Report Preview

Global Patient-Derived Xenograft Model Market By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer) By Model Type (Mice Type, Rats Type) By End User (Pharmaceutical & Biotechnology Companies, Academic and research institutes, CROs & CDMOs) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2031.

In 2021, the market for Patient-Derived Xenograft Model worldwide was worth $170 million US dollars. AMR Group projects that the market will reach US$ 512.4 million by 2031, growing at a CAGR of 13.2 percent between 2022 and 2031.

Industry Overview

Patient-Derived Xenograft/PDX model development has grown in popularity in recent years, with the expectation that certain systems will be more relevant than mouse as well as cell line models, and thus more informative and predictive preclinical therapeutic models. Recent research has shown that personalized PDX avatars can predict and even lead to tailored cancer treatment for patients. The ability of PDX models to function as true mouse avatars, on the other hand, is dependent on the preservation of each case’s unique molecular properties.

Because of the high intra-tumor complexity and geographic dispersion of different clones and metastases in many tumor forms, customized avatar modelling is difficult. However, there is evidence that once formed, PDX models are stable across multiple passes, resulting in a consistent, trustworthy system. The Patient-derived xenografts (PDX) refer to the models of cancer where cells or tissues from a tumor of a patient that are implanted into humanized or immune deficient mouse. These models are known to simulate human tumor biology that enables natural cancer progression. This provides translational research model in order to evaluate efficacy. Recent developments in gene expression technologies have provided the production of novel vaccines and biopharmaceuticals, thereby increasing the research & development applications of Patient-Derived Xenograft Model techniques.

Market Dynamics

The Patient-Derived Xenograft Model market is expected to grow due to rising cancer cases and increased R&D investment by major market players in the development of new Patient-Derived Xenograft Model products. According to the GLOBOCAN Report 2020, approximately 19,292,789 new cancer cases and 9,958,133 cancer deaths have been reported globally. Breast cancer, lung cancer, colorectum cancer, and prostate cancer are the most common cancers. Similarly, governments in various countries are taking steps to raise consciousness about cancer as well as its diagnosis so that it can be detected earlier. Also in 2022, the Health Minister of Tamil Nadu, State of India, stated that the Tamil Nadu government is working on a policy to identify 66.0% of cancer patients in the first and second stages by 2030, so that proper treatment can be provided. As a result, such a policy is expected to drive market growth. The efficacy of medicines is tested using xenograft animal models.

Prior to clinical development and testing in humans, the mouse model of cancer has continuously been utilized to determine the in vivo activity of new anti-cancer therapeutic applications. As a result, rising cancer cases and initiatives related to cancer diagnosis and treatment are expected to drive market growth over the forecast period. Moreover, the rising price of personalized patient-derived xenograft models as well as stringent regulations regarding the use of animal studies are likely to stymie market growth over the forecast period.

COVID Impact

The COVID-19 pandemic has positively impacted the Patient-Derived Xenograft Model Markets to develop both therapeutic and preventive drugs. Because the pandemic has increased the number of cancer cases and risk factors, more scientific studies are being carried out to study the outcome and investigate new novel treatment technologies. Cancer patients, for example, were more vulnerable to COVID-19, according to a study titled “Effects of cancer on patients with COVID-19, a recent systematic and meta-analysis of 63,019 participants” published in February 2021. Cancer has been associated with a rise in death rates in COVID-19 patients. Among COVID-19 cancer patients, those with lung cancer died at a higher rate than those without lung cancer. According to the study, immunocompromised cancer patients are more prone to serious complications and are more susceptible to COVID-19 than the general population, which can affect the prognosis of the disease.

Regional Trend

Geographically, North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa account for the majority of the global Patient-Derived Xenograft Model market. Because of factors such as rising cancer cases, increased private and public sector investments, and the presence of major players in the region, North America dominates the Patient-Derived Xenograft Model market globally. The Breast Cancer Society of Canada, awarded Precision Oncology Research a USD 350,000 grant in 2022. The selected breast cancer research project will focus on advancements in screening, detection, precision oncology, and patient-reported outcomes, with the goal of improving the care of Canadian women with breast cancer.

Because of the rising incidence of cancer in the region, Asia Pacific is expected to register a higher. The country section of the report also includes individual market impacting factors and changes in market regulation that affect current and future market trends. Downstream and upstream value chain analysis, technical trends and porter’s five forces analysis, and case studies are some of the data points used to forecast the market scenario for individual countries. Additionally, the presence and availability of global brands, as well as the challenges they face due to substantial or scarce competition from domestic and local brands, are taken into account when providing forecast analysis of country data.

Competitive Landscape

Key players operating in the global Patient-Derived Xenograft Model market are Aragen Bioscience, Biocytogen, Bioduro, Champions Oncology, Inc., Charles River Laboratories, Inc., Covance Inc., Creative Animodel, Crown Bioscience, Inc., EPO Berlin-Buch GmbH, Explora BioLabs, GemPharmatech Co., Ltd., Hera BioLabs, Horizon discovery Ltd., Oncodesign, Pharmatest Services Ltd., The Jackson Laboratory, Urolead, Urospehere SAS, Wuxi AppTec, Xenopat and Xentech among others. Recently, GemPharmatech (GemPharmatech Co., Ltd.) announced in July 2022 that it has signed a strategic licence agreement with Charles River Laboratories, Inc. for the exclusive spread of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. Beginning in 2023, Charles River will establish foundation colonies with commercially available models.

Key USP’s-

Professor Kamimura’s research group at Niigata University established a novel pancreatic carcinogenesis model in wild-type rats in April 2022, using the pancreas-targeted sequential hydrodynamic gene delivery method.

Market Segmentation

Based upon the Tumor Type used in Patient-Derived Xenograft Model market is segmented into major segments of Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer and Other Cancer in the Patient-Derived Xenograft Model process. Further it is categorized according to its process and utilization. Based on Model Type, the Patient-Derived Xenograft Model market is segmented into Mice Type and Rats Type. Among the Model Type segments, mice model type segment accounted for the maximum revenue share of 70.4% in 2021 of the Patient-Derived Xenograft Model market. The major factors contributing to the large market share of this segment as the mouse is the foremost mammalian model for examining human illness and health. The mice have a quick reproductive cycle and a long lifespan (one mouse year is equivalent to approximately 30 human years), which keeps the cost, time, and space required for the study manageable.

The Patient-Derived Xenograft Model market is further segmented into Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, as well as CROs & CDMOs. CROs and CDMOs had the highest revenue share of 43.5% and is expected to grow the fastest during the forecast period. Factors driving this segment’s large market share include high mergers and acquisitions, service expansion, and pharmaceutical and biopharmaceutical companies outsourcing their research activities, all of which will contribute to the segment’s growth.

By Tumor Type

• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer

 By Model Type

• Mice Type
• Rats Type

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CDMOs